Why Atossa Genetics (ATOS) Stock Hit a One-Year Low Today

NEW YORK (TheStreet) -- Shares of Atossa Genetics  (ATOS) plummeted to a 52-week low of $1.07 on Wednesday after the company announced the FDA had determined Atossa's ForeCYTE Breast Aspirator is "not substantially equivalent" to its predicate device and would not clear it for U.S. marketing.

Atossa will now prioritize the U.S. commercialization of another breast aspirator, the FullCYTE. Atossa acquired the FullCYTE, which the FDA has already cleared, in 2012. The FullCYTE is a subset of Atossa's FullCYTE Microcather, which Atossa has been preparing to commercialize during the last 12 months.

The stock closed down 42.49% to $1.34. More than 2.6 million shares changed hands, compared to the average volume of 473,281.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ATOS Chart ATOS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Insider Trading Alert - ATOS, EGLT And VRNS Traded By Insiders

Atossa (ATOS) Stock Up, FDA Accepts Fulvestrant Investigational Drug Application

4 Stocks Under $10 Triggering Breakout Trades

Atossa Genetics (ATOS) Stock Gains After Receiving Breast Cancer Detection Patent

Atossa Genetics (ATOS) Strong On High Relative Volume Today